Parexel

Parexel is a leading global clinical research organization (CRO) specializing in providing comprehensive services to the biopharmaceutical and medical device industries. Established in 1982, the company has grown to become one of the largest CROs worldwide. It offers a full spectrum of clinical development services from Phase I through Phase IV trials.

Services and Expertise

Parexel's extensive service offerings encompass:

• Clinical Trial Management: Designing and executing clinical trials across various therapeutic areas, including oncology, neuroscience, infectious diseases, and immunology.
• Regulatory Consulting: Assisting clients with navigating complex regulatory landscapes to achieve timely approvals.
• Data Management and Biostatistics: Providing robust data solutions and statistical analysis to ensure the integrity and reliability of clinical trial data.
• Medical Writing: Crafting comprehensive clinical documents, such as study protocols, investigator brochures, and clinical study reports.
• Pharmacovigilance: Monitoring and assessing the safety of pharmaceutical products to ensure patient well-being.
• Market Access Strategy: Developing strategies to facilitate the successful commercialization of new therapies.

By integrating these services, Parexel aims to streamline the drug development process. This reduces time to market and enhances the efficiency of bringing new treatments to patients.

Global Presence

With a workforce of over 24,000 professionals, Parexel operates in more than 80 locations across 51 countries. This extensive global reach enables the company to conduct clinical trials in diverse populations. It provides valuable insights into the safety and efficacy of treatments worldwide.

Their notable location includes:

• Norristown, PA, USA

Recent Developments

In September 2024, Parexel relocated its headquarters from Durham, North Carolina, to the North Hills Innovation District in Raleigh, North Carolina. This move reflects the company's commitment to innovation and strategic expansion in key markets.

Commitment to Patient-Centric Research

Parexel places a strong emphasis on patient-centric research, striving to make clinical trials more accessible and relevant to diverse patient populations. This dedication has been recognized with industry awards, including the 2023 and 2024 Society for Clinical Research Sites (SCRS) Eagle Award.

Through its comprehensive services, global presence, and unwavering commitment to innovation and patient care, Parexel continues to play a pivotal role in advancing the development and commercialization of new medical therapies worldwide.